Gene · 51592
Papers2,289
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,289
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Correlation of Dermatopathologic Findings and Autoantibody Subtypes in Dermatomyositis. | Am J Dermatopathol | 2026 | 41128466 | PubTator, text mining | PubMed |
| Anti-TIF-1γ-positive dermatomyositis associated with colorectal adenocarcinoma: a case report. | Dermatol Reports | 2026 | 40994344 | PubTator, text mining | PubMed |
| Dazukibart for the treatment of severe TIF1γ-positive juvenile dermatomyositis. | J Eur Acad Dermatol Venereol | 2026 | 40947860 | PubTator, text mining | PubMed |
| Muscle strength recovery in patients with idiopathic inflammatory myopathy with different myositis-specific autoantibodies. | Immunol Med | 2026 | 40726328 | PubTator, text mining | PubMed |
| Reticular rash in anti-TIF1-γ positive dermatomyositis. | Lancet Rheumatol | 2026 | 40578383 | PubTator, text mining | PubMed |
| Treatment Algorithms for Inflammatory Myopathies in Adults: from Guidelines to Clinical Practice. | Curr Treatm Opt Rheumatol | 2025 | 41728064 | PubTator, text mining | PubMed |
| Rituximab for Early-Onset Juvenile Dermatomyositis Complicated by Interstitial Lung Disease. | Case Rep Pediatr | 2025 | 41477441 | PubTator, text mining | PubMed |
| An Update on Dermatomyositis and Related Inflammatory Myopathies: Cutaneous Clues, Skeletal Muscle Involvement, and Advances in Pathogenesis and Treatment. | Muscles | 2025 | 41441445 | PubTator, text mining | PubMed |
| Novel use of deucravacitinib for treatment of recalcitrant TIF1-gamma dermatomyositis. | JAAD Case Rep | 2025 | 41311792 | PubTator, text mining | PubMed |
| Prognostic Implications of Myositis-Specific Autoantibodies on Mortality, Relapse, and Remission in Dermatomyositis Patients. | Eur J Neurol | 2025 | 41294374 | PubTator, text mining | PubMed |
| Case Report: Possible association between dermatomyositis and Trastuzumab Deruxtecan therapy of triple-negative breast cancer patient. | Front Immunol | 2025 | 41293157 | PubTator, text mining | PubMed |
| Association of clinical features and myositis-specific antibodies in idiopathic inflammatory myopathy: a retrospective study from southern China. | Front Immunol | 2025 | 41280916 | PubTator, text mining | PubMed |
| Fat-brain axis indicated by mutual impacts between body fat and brain phenotypes. | J Transl Med | 2025 | 41272839 | PubTator, text mining | PubMed |
| Case Report: Rituximab Treatment for Refractory Skin Involvement in Anti-TIF1γ Dermatomyositis Without Associated Malignancy. | Int J Rheum Dis | 2025 | 41271232 | PubTator, text mining | PubMed |
| Progressive myalgia as the sole manifestation of cancer-associated myositis: A case report and review of the literature. | Medicine (Baltimore) | 2025 | 41239588 | PubTator, text mining | PubMed |
| Trigeminal involvement in dermatomyositis with double positivity for anti-transcriptional intermediary factor 1 gamma and anti-Ku antibodies: A case report and literature review. | J Int Med Res | 2025 | 41218828 | PubTator, text mining | PubMed |
| The SCRIM score: a clinical tool for cancer risk-stratification in patients with idiopathic inflammatory myopathy. | Arthritis Res Ther | 2025 | 41188999 | PubTator, text mining | PubMed |
| Analytical performance of commercial myositis-specific autoantibody tests evaluated against immunoprecipitation assays as a reference standard: A systematic review and meta-analysis. | Semin Arthritis Rheum | 2025 | 41176843 | PubTator, text mining | PubMed |
| Anti-MDA5+ dermatomyositis following SARS-COV-2 infections: a systematic review. | Front Immunol | 2025 | 40963624 | PubTator, text mining | PubMed |
| Anti-TIF1-Gamma Autoantibodies-Positive Juvenile Dermatomyositis Associated With Interstitial Lung Disease: A Case Report. | Cureus | 2025 | 40951084 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51592/papers?page=5